PRE-EXPOSURE PROPHYLAXIS WITH HYDROXYCHLOROQUINE IN SANITARIES HIGHLY EXPOSED TO COVID-19. (COVIDNA) - COVIDNA

AVARRABIOMED - FUNDACIÓN MIGUEL SERVET0 个研究点目标入组 200 人开始时间: 2020年5月7日最近更新: 2020年9月28日

适应症

试验速览

暂无简介。

•1. Sanitary with high exposure to COVID-19 with training of doctor or DUE belonging to the health network of Navarra
•2. No previous diagnosis of COVID-19
•3. Not present symptoms compatible with COVID-19, neither present nor past
•4. Negative Ig M or Ig G negative immunochromatography test result for both
•5. You agree not to self-medicate with chloroquine, hydroxychloroquine, or other potential antivirals.
•6. That they give their written informed consent to participate in the trial
•7. Not being pregnant. To do this, if you suspect that you might be, you should have previously had a pregnancy test.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 200
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•1. Hypersensitivity to chloroquine or derivatives.
•2. Contraindication to taking hydroxychloroquine (for epilepsy, severe kidney failure (clearance <10 ml / min), severe liver failure).
•3. Known retinopathy.
•4. Impossibility to continue in the trial during the 6 weeks of treatment.
•5. Taking concomitant contraindicated medication: aremeter / lumefantrine and mefloquine as antimalarials, natalizumab, pimecrolimus and tacroliums, moxifloxacin, agasidase alfa and beta, dapsone, tratuzumab, drugs that lengthen QT such as digoxin, amiodarone and some beta blockers.
•6. Pregnancy or pregnancy wish in the next 6 weeks.
•7. Glucose 6-Phosphate Dehydrogenase deficiency that generates hereditary hemolytic anemia.

发起方

AVARRABIOMED - FUNDACIÓN MIGUEL SERVET